Is it possible to reduce cardiovascular risk with glucose-lowering approaches?
- 1 May 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Endocrinology
- Vol. 5 (5) , 270-275
- https://doi.org/10.1038/nrendo.2009.49
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic ReviewArchives of internal medicine (1960), 2008
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trialAmerican Heart Journal, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Rosiglitazone RECORD study: glucose control outcomes at 18 monthsDiabetic Medicine, 2007
- Baseline characteristics of the randomised cohort from the Look AHEAD (Action for Health in Diabetes) studyDiabetes and Vascular Disease Research, 2006
- Rationale, Design, and Methods for Glycemic Control in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) TrialThe American Journal of Cardiology, 2006
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialPublished by Elsevier ,2005